EncarnaciĆ³n-Rosado, Joel
Kimmelman, Alec C.
Article History
Accepted: 16 February 2021
First Online: 19 March 2021
Competing interests
: A.C.K. has financial interests in Vescor Therapeutics and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, and the autophagic control of iron metabolism. A.C.K. is on the scientific advisory board of Rafael/Cornerstone Pharmaceuticals and is a consultant for Deciphera and Abbvie. The other author declares no competing interests.